A multimodal initiative improves general pediatric provider management of atopic dermatitis in children: A prospective interventional study - 10/10/23
Doi : 10.1016/j.jaad.2023.02.065
Stephanie S. Lee, MD a, b, Anshika Kaushik, MD c, Nicola Natsis, MD a, b, Ayan Kusari, MD d, David Schairer, MD a, b, Sarah Lindback, MD b, Mark Levenberg, DO e, J. Rebecca Mills, DrPH e, Kathleen Peeples, PharmD e, Richard Smith, PharmD e, Lawrence F. Eichenfield, MD a, b, f, ⁎ 
a Department of Dermatology, San Diego School of Medicine, University of California, La Jolla, California
b Rady Children’s Hospital San Diego, San Diego, California
c Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana
d Department of Dermatology, University of California, San Francisco, San Francisco, California
e Pfizer Inc., Collegeville, Pennsylvania
f Department of Pediatrics, San Diego School of Medicine, University of California, La Jolla, California
∗Correspondence to: Lawrence Eichenfield, MD, 3020 Children’s Way, Mail Code 5092, San Diego, CA 921233020 Children’s Way Mail Code 5092San DiegoCA92123
Key words : atopic dermatitis, child, electronic health record, pediatricians, quality improvement, topical drug administration
| Funding sources: Study activities for this project were funded by Pfizer Inc and the Rady/UCSD Eczema and Inflammatory Skin Disease Center. |
|
| IRB approval status: This study was exempt from IRB approval. |
|
| Shared data: The data that support the findings of this study are available from the corresponding author upon reasonable request. |
|
| Editorial support under the guidance of authors was provided by Lisa M. Klumpp Callan, PhD, of ApotheCom, San Francisco, CA, and was funded by Pfizer Inc, New York, NY, in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461-464). |
© 2023
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 89 - N° 5
P. 1041-1044 - novembre 2023 Retour au numéro
Article précédent
- Significant discordance in DermTech test results when paired with histopathology: Caveat emptor
- Jonathan Bass, Hannah Hill, Christine Jaworsky
- Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience
- Abdulhadi Jfri, Cesar A. Virgen, Marianne Tawa, Anita Giobbie-Hurder, Thomas S. Kupper, David C. Fisher, Nicole R. LeBoeuf, Cecilia Larocca
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?